NSGENE
NsGene is a Danish Biotech company located in the Medicon Valley region. The Company is committed to developing novel biological products for the treatment of neurological diseases and is focusing on multiple indications with high unmet needs, including Alzheimer's disease, epilepsy, neuropathic pain and Parkinson's disease.
NSGENE
Industry:
Biopharma Biotechnology Neuroscience
Founded:
1999-01-01
Address:
Ballerup, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.nsgene.dk
Total Employee:
11+
Status:
Closed
Contact:
4544608989
Total Funding:
5.69 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Nginx Amazon CloudFront Google Adsense AWS Global Accelerator AdBlock Acceptable Ads Google Adsense For Domains
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Enterin
Philadelphia-based biotechnology company .
Current Employees Featured
Founder
Investors List
Vaekstfonden
Vaekstfonden investment in Venture Round - NsGene
DKA Capital
DKA Capital investment in Venture Round - NsGene
Neurosearch
Neurosearch investment in Venture Round - NsGene
Karolinska
Karolinska investment in Venture Round - NsGene
LD Pensions
LD Pensions investment in Venture Round - NsGene
Official Site Inspections
http://www.nsgene.dk Semrush global rank: 5.64 M Semrush visits lastest month: 1.49 K
- Host name: cp05.nordicway.dk
- IP address: 144.76.115.20
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "NsGene"
NsGene - Crunchbase Company Profile & Funding
NsGene is a Danish Biotech company located in the Medicon Valley region. The Company is committed to developing novel biological products for the …See details»
NsGene A/S - Drug pipelines, Patents, Clinical trials - Synapse
NsGene's NGF secreting ECB device (NsG0202) combines the potential benefits of targeted gene therapy with the safety of a retrievable implantable device. The study is an open label, single …See details»
NsGene A/S - LinkedIn
NsGene is committed to developing novel biological products for the treatment of neurological diseases and is focusing on Alzheimer’s disease, Parkinson's disease and sensorineural hearing loss.See details»
NsGene Company Profile | Management and Employees List
NsGene Profile and History. NsGene was founded in December 1999 as a spin-off from the Danish biopharmaceutical company, NeuroSearch A/S, to develop novel cell and gene based …See details»
NsGene - VentureRadar
Gloriana Therapeutics is a Rhode Island-based biotechnology company developing proprietary Encapsulated Cell (EC) products for the treatment of neurological disorders. The Company …See details»
NsGene A/S - VentureRadar
NsGene is a Denmark and US-based biotechnology company located in the greater Copenhagen area and in Providence, RI. Founded in 1999 in Denmark, the company more recently …See details»
NsGene - Overview, News & Similar companies | ZoomInfo.com
NsGene contact info: Phone number: +45 44608900 Website: www.nsgene.dk What does NsGene do? NsGene was founded in December 1999 as a spin-off from the Danish …See details»
NsGene A/S - Detailed information - Largestcompanies
DK-2750 Ballerup County: Capital Region of Denmark Municipality: Ballerup ... Telephone: +45 44608900 Website: www.nsgene.dk CFAR: 1004963390 Established: 1999 Listing: Not listed …See details»
NsGene (Denmark) - Wikidata
Company in Ballerup, DenmarkSee details»
NsGene A/S - Company Profile and News - Bloomberg Markets
NsGene A/S is a biotechnology company. The Company develops biological products that treat neurological diseases such as Alzeimer's disease, epilepsy, neuropathic pain, and Parkinson's …See details»
NsGene - Products, Competitors, Financials, Employees, …
NsGene is a biotechnology company. It identifies neurotrophic proteins with therapeutic effects in the nervous system and develops technologies to target protein therapeutics across the blood …See details»
NsGene - Funding, Financials, Valuation & Investors - Crunchbase
NsGene develops products for the treatment of neurological, alzheimer’s, and parkinson's disease and sensorineural hearing loss.See details»
NsGene | VentureRadar
Website: http://www.nsgene.dk/ NsGene is committed to developing novel biologics for the treatment of neurological diseases and NsGene’s R&D activities are focused on a proprietary …See details»
NeuroSearch announces that 27%-owned NsGene A/S signs new
Aug 10, 2010 · Teit E. Johansen, CEO of NsGene, said, “NsGene is pleased to hand over the full control of the commercialisation of Neublastin to Biogen Idec.See details»
NsGene receives $545K to develop neuro-disorder treatment device
NSGENE INC., a biotech company based in Denmark and Providence, will develop its BrainRepair platform to treat cortico-basal degeneration, a rare neurological disorder with …See details»
Ny behandling af Alzheimers: "Tepose" i hjernen udsender medicin
Dec 14, 2007 · De får et tepose-lignende reservoir med levende menneskeceller indopereret i hjernen. Cellerne producerer proteiner, der virker som medicin. Den nye metode til at få …See details»
Takeda and NsGene to research encapsulated cell therapies
Jan 8, 2016 · NsGene will receive funding from Takeda for technology development that enables NsGene to complete critical scientific milestones. The partnership will focus on the delivery of …See details»
NsGene A/S (NsGene A/S) - 药物管线_专利_临床试验_投融营收_最 …
NsGene's NGF secreting ECB device (NsG0202) combines the potential benefits of targeted gene therapy with the safety of a retrievable implantable device. The study is an open label, single …See details»
Research programme: epilepsy therapies - NsGene - AdisInsight
Jul 16, 2016 · NsGene in Denmark is developing therapies for the treatment of epilepsy using its proprietary Encapsulated Cell (EC) Biodelivery™ technology. The technology.See details»
Generation of a variety of stable Influenza A reporter viruses by ...
Jun 12, 2015 · Based on this favorable property of PTV-1 2A, we engineered influenza A viruses harboring an NS segment encoding reporter genes flanked by two genetically distinct PTV-1 …See details»